摘要
帕金森病(Parkinson’s disease,PD)是一种黑质神经元发生损伤坏死的中枢神经退行性疾病。现在以药物治疗为主要手段,现有药物主要作用在关键信号靶点以缓解病情,但未能彻底修复变性神经元。近几年细胞治疗技术逐渐渗入到临床试验,已然成为社会焦点。骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMSCs)是一种成体多能干细胞,其自我增殖和多向分化能力已被公认。BMSCs可以应用于PD中以探索更加有效的治疗策略。黄芪甲苷是中药黄芪的特征成分,具有抗炎,抗氧化以及抗凋亡等活性作用。另外黄芪甲苷对神经干细胞具有保护作用,研究亦发现黄芪甲苷在PD模型中发挥保护神经作用。该文就BMSCs治疗PD现状和黄芪甲苷对PD治疗作用的研究进展作一综述,以此为基础提出了黄芪甲苷诱导骨髓间充质干细胞治疗帕金森病的新思路。
Parkinson’s disease (PD) is a kind of neurodegenerative diseases of the central nervous system in which substantia nigra neurons are damaged and necrotic.At present,PD is mainly treated with drugs which affect the key molecular in the pathogenesis of PD or signaling pathway to alleviate the disease,however,denatured neuron could not be completely repaired. In recent years,cell therapy technology has gradually infiltrated into clinical trials and became a social focus.Bone marrow mesenchymal stem cells(BMSCs),a kind of adult pluripotent stem cells,have self-proliferation and multi-directional differentiation capabilities and are applied to explore more effective strategies for PD treatment.Astragaloside Ⅳ,a characteristic component of traditional Chinese medicine Astragalus,possesses anti-inflammatory,anti-oxidative and antiapoptotic activities.What’s more,Astragaloside Ⅳ has a protective effect on neural stem cells,and the study demonstrated that Astragaloside Ⅳ plays a neuroprotective role in PD model.This article reviewed the research progress of BMSCs and Astragaloside IV in the treatment of PD.A new idea that Astragaloside Ⅳ induced BMSCs to treat PD is proposed based on above of conclusions.
作者
高志红
左亚奇
张晓丽
GAO Zhi-hong;ZUO Ya-qi;ZHANG Xiao-li(Hebei North University,Basic Medical Collage,Zhangjiakou,075000,China;Hebei North University School of Pharmacy,Zhangjiakou,075000,China)
出处
《神经药理学报》
2017年第5期39-44,共6页
Acta Neuropharmacologica
基金
河北省高等学校科学技术研究项目(No.ZD2014067)
河北北方学院校级科研项目(No.YB2018008).
关键词
帕金森病
骨髓间充质细胞
黄芪甲苷
治疗策略
Parkinson’s disease
bone marrow mesenchymal cells
astragaloside
treatment
